UBS Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-402,893
| Closed | -$1.69M | – | 10428 |
|
|
2023
Q1 | $1.69M | Sell |
402,893
-523,416
| -57% | -$2.72M | ﹤0.01% | 3600 |
|
|
2022
Q4 | $5.57M | Buy |
926,309
+782,053
| +542% | +$4.27M | ﹤0.01% | 2399 |
|
|
2022
Q3 | $840K | Sell |
144,256
-133,244
| -48% | -$830K | ﹤0.01% | 3901 |
|
|
2022
Q2 | $1.66M | Buy |
277,500
+260,766
| +1,558% | +$1.34M | ﹤0.01% | 3309 |
|
|
2022
Q1 | $78K | Buy |
16,734
+12,717
| +317% | +$37.9K | ﹤0.01% | 6094 |
|
|
2021
Q4 | $10K | Sell |
4,017
-261
| -6% | -$639 | ﹤0.01% | 8872 |
|
|
2021
Q3 | $13K | Sell |
4,278
-2,469
| -37% | -$6.72K | ﹤0.01% | 7731 |
|
|
2021
Q2 | $17K | Sell |
6,747
-3,224
| -32% | -$7.73K | ﹤0.01% | 7551 |
|
|
2021
Q1 | $29K | Buy |
9,971
+5,693
| +133% | +$18.6K | ﹤0.01% | 7059 |
|
|
2020
Q4 | $14K | Sell |
4,278
-584
| -12% | -$1.94K | ﹤0.01% | 7258 |
|
|
2020
Q3 | $10K | Sell |
4,862
-21,000
| -81% | -$26.8K | ﹤0.01% | 6904 |
|
|
2020
Q2 | $30K | Buy |
25,862
+8,195
| +46% | +$8.66K | ﹤0.01% | 6288 |
|
|
2020
Q1 | $16K | Buy |
17,667
+8,263
| +88% | +$9.47K | ﹤0.01% | 6662 |
|
|
2019
Q4 | $15K | Buy |
9,404
+5,328
| +131% | +$5.05K | ﹤0.01% | 7079 |
|
|
2019
Q3 | $3K | Sell |
4,076
-4,109
| -50% | -$3.14K | ﹤0.01% | 7707 |
|
|
2019
Q2 | $7K | Buy |
8,185
+2,255
| +38% | +$2.08K | ﹤0.01% | 7295 |
|
|
2019
Q1 | $6K | Sell |
5,930
-26,451
| -82% | -$27.9K | ﹤0.01% | 7134 |
|
|
2018
Q4 | $24K | Buy |
32,381
+6,576
| +25% | +$10.8K | ﹤0.01% | 6660 |
|
|
2018
Q3 | $56K | Buy |
25,805
+5,398
| +26% | +$13.4K | ﹤0.01% | 6084 |
|
|
2018
Q2 | $101K | Buy |
20,407
+5,252
| +35% | +$23K | ﹤0.01% | 5439 |
|
|
2018
Q1 | $59K | Buy |
15,155
+3,979
| +36% | +$14K | ﹤0.01% | 5593 |
|
|
2017
Q4 | $30K | Buy |
11,176
+3,973
| +55% | +$11.6K | ﹤0.01% | 6252 |
|
|
2017
Q3 | $23K | Buy |
7,203
+2,865
| +66% | +$9.57K | ﹤0.01% | 6369 |
|
|
2017
Q2 | $14K | Sell |
4,338
-479
| -10% | -$1.86K | ﹤0.01% | 6584 |
|
|
2017
Q1 | $20K | Sell |
4,817
-3,867
| -45% | -$17.8K | ﹤0.01% | 6155 |
|
|
2016
Q4 | $35K | Sell |
8,684
-532
| -6% | -$2.21K | ﹤0.01% | 6127 |
|
|
2016
Q3 | $34K | Buy |
9,216
+7,791
| +547% | +$28.4K | ﹤0.01% | 5829 |
|
|
2016
Q2 | $5K | Buy |
1,425
+1,319
| +1,244% | +$6.05K | ﹤0.01% | 7191 |
|
|
2016
Q1 | $1K | Sell |
106
-965
| -90% | -$7.71K | ﹤0.01% | 7546 |
|
|
2015
Q4 | $13K | Buy |
1,071
+935
| +688% | +$12.5K | ﹤0.01% | 7150 |
|
|
2015
Q3 | $2K | Hold |
136
| – | – | ﹤0.01% | 8163 |
|
|
2015
Q2 | $3K | Sell |
136
-4,369
| -97% | -$84.3K | ﹤0.01% | 8149 |
|
|
2015
Q1 | $81K | Buy |
4,505
+3,538
| +366% | +$79.6K | ﹤0.01% | 5606 |
|
|
2014
Q4 | $23K | Buy |
+967
| New | +$22.4K | ﹤0.01% | 7497 |
|
Other funds holding CTIC
UBS Group's CTIC Position: Q2 2023 in Review
UBS Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 402,893 shares — an estimated $1.69M sold.
UBS Group first reported a position in CTIC in Q4 2014 and held it in 34 quarters. The position peaked at $5.57M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- UBS Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- UBS Group sold 402,893 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $1.69M.
- UBS Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2014 and held it in 34 quarters.
- UBS Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $5.57M in Q4 2022.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.